Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Pulmonary Hypertension

Free Subscription 12.01.2026 1 A A Pract 1 Acta Med Indones 1 Anal Chem 1 Biomed Pharmacother 1 BMC Public Health 2 BMC Pulm Med 1 BMJ Case Rep 1 Bull Exp Biol Med 1 Can J Cardiol 1 Cardiovasc Res 1 Cardiovasc Toxicol 1 Cell Signal 1 Chest 1 Circ Heart Fail 1 Compr Physiol 1 COPD 1 Cureus 1 Curr Cardiol Rep 2 Diagnostics (Basel) 2 Echocardiography 1 Eur Heart J Case Rep 1 Genes Dis 1 Hypertension 1 Int J Cardiol 1 Int J Mol Sci 1 Intern Med 1 J Biomech Eng 1 J Cardiothorac Vasc Anesth 2 J Clin Med 1 J Genet Genomics 1 J Sex Med 1 J Vis Exp 1 Mediators Inflamm 2 Medicine (Baltimore) 1 Nihon Yakurigaku Zasshi 1 Orv Hetil 1 Pulm Circ 1 Respir Investig 1 Respir Res 1 Semin Respir Crit Care Med 1 Signal Transduct Target Ther 1 Thorax 1 Transl Pediatr 1 Zhonghua Jie He He Hu Xi Za Zhi

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

A A Pract

1. ARTHUR ME, Mudaliar P, Sakharpe A, Odo N, et al
   Between a Rock and a Hard Place: Hip Fracture Repair in an Elderly Patient with Severe Cardiac Comorbidities and Limited Options: A Problem-Based Learning Discussion.
   A A Pract. 2026;20:e02058.
   PubMed         Abstract available
   
   

   
   Acta Med Indones

2. MIRZAMOHAMMADI S, Shirazi N, Deravi N, Zadeh RH, et al
   Coronary Artery Calcium Score as a Potential Non-Invasive Marker for Pulmonary Artery Hypertension.
   Acta Med Indones. 2025;57:445-453.
   PubMed         Abstract available
   
   

   
   Anal Chem

3. WANG X, Song X, Yu F, Yu Y, et al
   A Superoxide Anion-Responsive NIR Fluorogenic Probe Unravels Aucubin's Dual-Axis Therapeutic Mechanism in Hypoxic Pulmonary Hypertension via Ferroptosis Suppression and Oxidative Injury Mitigation.
   Anal Chem. 2026 Jan 7. doi: 10.1021/acs.analchem.5c05233.
   PubMed         Abstract available
   
   

   
   Biomed Pharmacother

4. LI G, Zhao Z, Machitani M, Ishikawa R, et al
   Elucidation of mechanisms underlying the therapeutic effects of cordycepin on pulmonary hypertension, with a focus on cell senescence and gut microbiota.
   Biomed Pharmacother. 2026;194:118923.
   PubMed         Abstract available
   
   

   
   BMC Public Health

5. GUAN A, Dai Z, Lin J, Chen Q, et al
   Global disease burden of pulmonary arterial hypertension: patterns and inequality in 1990-2021, with projections to 2035.
   BMC Public Health. 2026;26:4.
   PubMed         Abstract available
   
   

   
   BMC Pulm Med

6. ROSHANZAMIR Z, Mohammadi F, Shirzadi R
   Pulmonary hypertension in pediatric patients with cystic fibrosis during acute pulmonary exacerbations: prevalence and associated factors.
   BMC Pulm Med. 2026 Jan 3. doi: 10.1186/s12890-025-04095.
   PubMed         Abstract available
   
   
7. KAM THH, Kam KKH, Wong MKL, Yan BPY, et al
   Haemodynamic and clinical impacts of switching phosphodiesterase-5 inhibitors to riociguat in patients with chronic thromboembolic pulmonary hypertension (CTEPH) after balloon pulmonary angioplasty (BPA) - a prospective cohort study.
   BMC Pulm Med. 2026 Jan 3. doi: 10.1186/s12890-025-04069.
   PubMed         Abstract available
   
   

   
   BMJ Case Rep

8. SEERAM VK, Boppana LKT
   Unilateral absence of pulmonary artery presenting with pulmonary hypertension in two adults.
   BMJ Case Rep. 2026;19:e269028.
   PubMed         Abstract available
   
   

   
   Bull Exp Biol Med

9. VACHRUSHEV NS, Karpov AA, Shilenko LA, Vaulina DD, et al
   Lung Tissue RNA Sequencing Shows Dysregulation of the Bronchial Epithelium in a Rat Model of Chronic Thromboembolic Pulmonary Hypertension.
   Bull Exp Biol Med. 2026 Jan 9. doi: 10.1007/s10517-026-06549.
   PubMed         Abstract available
   
   

   
   Can J Cardiol

10. SOMECH J, Zahler D, St-Germain R, Roshdy O, et al
    Rapidly reversible precapillary pulmonary hypertension in a patient with scurvy.
    Can J Cardiol. 2026 Jan 2:S0828-282X(25)01621-6. doi: 10.1016/j.cjca.2025.
    PubMed        
    
    

    
    Cardiovasc Res

11. PAK O, Weissmann N
    Is it the extracellular matrix?-smooth muscle fate in pulmonary hypertension secondary to left heart disease.
    Cardiovasc Res. 2026 Jan 7:cvaf261. doi: 10.1093.
    PubMed        
    
    

    
    Cardiovasc Toxicol

12. ZHANG Y, Ye J, Chen J, Chen J, et al
    Pharmacovigilance Analysis of Sotatercept for the Treatment of Pulmonary Arterial Hypertension Based on FAERS Database.
    Cardiovasc Toxicol. 2026;26:12.
    PubMed         Abstract available
    
    

    
    Cell Signal

13. WANG M, Zhang M, Chen J, Wang Y, et al
    Nuclear SIRT6 depletion activates LINE1-cGAS-STING pathway to induce PASMCs senescence in hypoxic pulmonary hypertension.
    Cell Signal. 2026;139:112351.
    PubMed         Abstract available
    
    

    
    Chest

14. YANG JZ, Madani MM, Papamatheakis DG, Fernandes TM, et al
    CHEST How I Do It: Management of chronic thromboembolic pulmonary hypertension before and after pulmonary thromboendarterectomy.
    Chest. 2026 Jan 2:S0012-3692(25)05963-X. doi: 10.1016/j.chest.2025.
    PubMed         Abstract available
    
    

    
    Circ Heart Fail

15. BELKIN MN, Fudim M, Baratto C, Grinstein J, et al
    Standardization of Baseline and Provocative Invasive Hemodynamic Protocols for the Evaluation of Heart Failure and Pulmonary Hypertension: A Scientific Statement From the American Heart Association.
    Circ Heart Fail. 2026 Jan 6:e000088. doi: 10.1161/HHF.0000000000000088.
    PubMed         Abstract available
    
    

    
    Compr Physiol

16. QIU Y, Lyu X, Zhang D, Xu H, et al
    Gut Microbiota in Pulmonary Arterial Hypertension: Murine Models and Human Microbial Signatures, Pathogenic Mechanisms, and Emerging Therapeutic Avenues.
    Compr Physiol. 2026;16:e70094.
    PubMed         Abstract available
    
    

    
    COPD

17. KHAN SA, Parikh T, Rao A, Agrawal A, et al
    In-hospital Mortality Patterns and Readmissions in Patients With Chronic Obstructive Pulmonary Disease: An Analysis of the Role of Pulmonary Hypertension.
    COPD. 2026;23:2582902.
    PubMed         Abstract available
    
    

    
    Cureus

18. HEGAZY Y, Abdallah A, Salem A, Assaker A, et al
    When the Skin Tells a Pulmonary Story: A Case of Neurofibromatosis Type 1-Associated Pulmonary Hypertension.
    Cureus. 2025;17:e98338.
    PubMed         Abstract available
    
    

    
    Curr Cardiol Rep

19. DAOUD A, Lopez PP, Mombeini H, Zaeske A, et al
    Echocardiographic Deformation Imaging of the Right Atrium: A New Paradigm in Noninvasive Hemodynamic Assessment.
    Curr Cardiol Rep. 2026;28:11.
    PubMed         Abstract available
    
    

    
    Diagnostics (Basel)

20. PAGNONI G, Vicenzi A, Coppi F
    Clarifying the Clinical Utility of NTAR/RGR for PAH and CTEPH. Comment on Iancu et al. Evaluating NT-proBNP-to-Albumin (NTAR) and RDW-to-eGFR (RGR) Ratios as Biomarkers for Predicting Hospitalization Duration and Mortality in Pulmonary Arterial Hypert
    Diagnostics (Basel). 2025;16:55.
    PubMed         Abstract available
    
    
21. IANCU DG, Cristescu L, Mares RG, Varga A, et al
    Reply to Pagnoni et al. Clarifying the Clinical Utility of NTAR/RGR for PAH and CTEPH. Comment on "Iancu et al. Evaluating NT-proBNP-to-Albumin (NTAR) and RDW-to-eGFR (RGR) Ratios as Biomarkers for Predicting Hospitalization Duration and Mortality in
    Diagnostics (Basel). 2025;16:56.
    PubMed         Abstract available
    
    

    
    Echocardiography

22. MIHAI A
    Right Ventricular Global Wasted Work and RV-PA Coupling: Implications for Pulmonary Hypertension.
    Echocardiography. 2026;43:e70384.
    PubMed        
    
    
23. VENKATESHVARAN A, Lindow T, Jumatate R, Kovacs A, et al
    Linking Energetic Inefficiency to Ventriculoarterial Uncoupling in Pulmonary Hypertension.
    Echocardiography. 2026;43:e70389.
    PubMed         Abstract available
    
    

    
    Eur Heart J Case Rep

24. SHIMOJO T, Tada T, Ito H, Kinoshita H, et al
    Pulmonary tumour thrombotic microangiopathy or chronic thromboembolic pulmonary hypertension?-diagnosed by pulmonary wedge aspiration cytology using a Swan-Ganz catheter: a case report.
    Eur Heart J Case Rep. 2025;10:ytaf648.
    PubMed         Abstract available
    
    

    
    Genes Dis

25. WANG Q, Liu J, Li R, Kong S, et al
    Macrophage kappa-opioid receptor inhibits hypoxic pulmonary hypertension progression and right heart dysfunction via an SCD1-dependent anti-inflammatory response.
    Genes Dis. 2025;13:101604.
    PubMed         Abstract available
    
    

    
    Hypertension

26. HAO J, Fang G, Li X, Wang T, et al
    Targeting Macrophage Crosstalk to PASMC by Blunting Inflammatory Phenotype Via SerpinB1 Protects Against Hypoxia-Induced Pulmonary Hypertension.
    Hypertension. 2026 Jan 7. doi: 10.1161/HYPERTENSIONAHA.125.25832.
    PubMed         Abstract available
    
    

    
    Int J Cardiol

27. NAEEM A, Bolaji O, Kidess GG, Fahed J, et al
    Durability of sotatercept response in pulmonary hypertension: Insights from extended real-world follow-up.
    Int J Cardiol. 2026;447:134150.
    PubMed         Abstract available
    
    

    
    Int J Mol Sci

28. ZHANG X, Chen M, Wang R, Liu R, et al
    Flavonoids: Potential New Drug Candidates for Attenuating Vascular Remodeling in Pulmonary Hypertension.
    Int J Mol Sci. 2025;27:210.
    PubMed         Abstract available
    
    

    
    Intern Med

29. YOKOKAWA T, Nishiura K, Akama J, Kiko T, et al
    Significance of 14-3-3 Epsilon for Right Ventricular Failure Associated with Pulmonary Hypertension.
    Intern Med. 2026 Jan 2. doi: 10.2169/internalmedicine.6383.
    PubMed         Abstract available
    
    

    
    J Biomech Eng

30. BAHMANI F, Pearce D, Southern K, Nwadiaro K, et al
    Fluid Flow Analysis of Pulmonary Hypertension in End Stage Renal Disease: A NAMS-Driven Case Study.
    J Biomech Eng. 2026 Jan 5:1-29. doi: 10.1115/1.4070760.
    PubMed         Abstract available
    
    

    
    J Cardiothorac Vasc Anesth

31. OLLOSU M, Tripodi VF, Aresu C, Ledda G, et al
    Efficacy and Safety of Pulmonary Vasodilator and Inodilator Drugs in Congenital Heart Disease Surgery: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    J Cardiothorac Vasc Anesth. 2026;40:333-346.
    PubMed         Abstract available
    
    

    
    J Clin Med

32. KOOK H, Kim W, Heo R, Kim K, et al
    Current Perspectives on Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension.
    J Clin Med. 2025;15:51.
    PubMed         Abstract available
    
    
33. AKOPYAN K, Peterson J, Amoda O, Khasawneh M, et al
    Echocardiographic Pulmonary Hypertension in Patients Positive for Myositis-Specific and Myositis-Associated Antibodies.
    J Clin Med. 2025;15:77.
    PubMed         Abstract available
    
    

    
    J Genet Genomics

34. ZHI C, Shi X, Chen S, Cai Z, et al
    Single-cell transcriptome analysis reveals critical causative candidates for Down syndrome-related lung diseases.
    J Genet Genomics. 2026;53:75-86.
    PubMed         Abstract available
    
    

    
    J Sex Med

35. QIAO X, Su D, Qin S, Shang L, et al
    Pulmonary arterial hypertension increases the risk of female sexual dysfunction: a systematic review and meta-analysis.
    J Sex Med. 2026;23:qdaf294.
    PubMed         Abstract available
    
    

    
    J Vis Exp

36. DING H, Zeng M, Sun B, Deng F, et al
    Measurement of Pulmonary Artery Pressure in Rats Using Right Heart Catheterization.
    J Vis Exp. 2025;.
    PubMed         Abstract available
    
    

    
    Mediators Inflamm

37. HUANG Y, Yan S, Zhu J, Zhang W, et al
    SPP1 May Play an Important Role in the Carcinoid Nature of PAH.
    Mediators Inflamm. 2025;2025:7457106.
    PubMed         Abstract available
    
    

    
    Medicine (Baltimore)

38. KIM TH, Youn SE, Chung SH
    Clinical impact of treprostinil in neonates with persistent pulmonary hypertension refractory to inhaled nitric oxide: A retrospective cohort study.
    Medicine (Baltimore). 2026;105:e46984.
    PubMed         Abstract available
    
    
39. YUE K, Qu X, Zhang F, Zhao M, et al
    Pulmonary hypertension caused by fibrosing mediastinitis: A case report and literature review.
    Medicine (Baltimore). 2026;105:e46180.
    PubMed         Abstract available
    
    

    
    Nihon Yakurigaku Zasshi

40. KURAHARA LH
    [Cellular senescence in pulmonary hypertension].
    Nihon Yakurigaku Zasshi. 2026;161:55-56.
    PubMed        
    
    

    
    Orv Hetil

41. BARANYAI T, Takacs P, Szabo B, Nagy Z, et al
    [Balloon pulmonary angioplasty in Gottsegen National Cardiovascular Center - results of the first 2 years].
    Orv Hetil. 2026;167:23-29.
    PubMed         Abstract available
    
    

    
    Pulm Circ

42. PRISCO SZ, Kantorovich A, Liu Y, Sahay S, et al
    Global Resource Disparities Between Pulmonary Hypertension Centers: Results From the International Survey by the PVRI IDDI Access to Care Workstream.
    Pulm Circ. 2026;16:e70229.
    PubMed         Abstract available
    
    

    
    Respir Investig

43. KONDOH Y, Ogura T, Nishiyama O, Kinoshita H, et al
    Corrigendum to "Long-term effects of inhaled treprostinil in Japanese patients with pulmonary hypertension associated with interstitial lung disease" [Respir Invest, Volume 64, Issue 1, January 2026, 101340].
    Respir Investig. 2026 Jan 6:101365. doi: 10.1016/j.resinv.2025.101365.
    PubMed        
    
    

    
    Respir Res

44. HAN R, Wang Y, Lu X, Li W, et al
    Comprehensive profiling of lactylation-associated genes in pulmonary hypertension through bulk and single-cell RNA sequencing integration.
    Respir Res. 2026 Jan 3. doi: 10.1186/s12931-025-03446.
    PubMed         Abstract available
    
    

    
    Semin Respir Crit Care Med

45. SPAGNOLO P, Dhanani Z, Cameli P, Fiorentu G, et al
    Advanced Pulmonary Sarcoidosis.
    Semin Respir Crit Care Med. 2025;46:564-575.
    PubMed         Abstract available
    
    

    
    Signal Transduct Target Ther

46. ADU-AMANKWAAH J, Shi Y, Song H, Ma Y, et al
    Correction: Signaling pathways and targeted therapy for pulmonary hypertension.
    Signal Transduct Target Ther. 2026;11:12.
    PubMed        
    
    

    
    Thorax

47. MINATSUKI S, Hatano M, Funakoshi K, Taniguchi Y, et al
    Significance of diffusing capacity of the lungs for carbon monoxide on chronic thromboembolic pulmonary hypertension.
    Thorax. 2026 Jan 7:thorax-2025-223670. doi: 10.1136/thorax-2025-223670.
    PubMed         Abstract available
    
    

    
    Transl Pediatr

48. ZHU Y, He J, Cai M, Wen L, et al
    Safety of a novel portable inhaled nitric oxide generator for therapy of persistent pulmonary hypertension in neonates: a case series study.
    Transl Pediatr. 2025;14:3305-3317.
    PubMed         Abstract available
    
    

    
    Zhonghua Jie He He Hu Xi Za Zhi

49. LIU BY, Xie M
    [Application and research progress of artificial intelligence in the diagnosis and treatment of rare lung diseases].
    Zhonghua Jie He He Hu Xi Za Zhi. 2026;49:78-83.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Pulmonary Hypertension is free of charge.